While doing a bit of research on another of my biotech investments, I came across a piece of info I figured I'd pass along. It might prove of value in the near future as the partnering process matures for CABO.
Come to find that Gisela Schwab was named to the Board of Directors of Topotarget on Sept 29,2011. Located in Denmark, TOPO is an oncology bio traded on the Copenhagen X-change. This is the same outfit that is partnered w/ SPPI for belinostat in Europe. This could be a significant development...no? GLTA
partnering doesn't make sense unless a strong partner is involved who can provide not only deep financial resources, but also commercial and regulatory experience. they don't appear to have either.. only about $50 MM of cash left. they seem to have recruited Dr. Schwab for her experience in advancing early stage compounds. from their 2Q report:
"[Dr. Schwab] has great experience within the pharmaceutical industry in managing early and late stage development activities (target selection, pre-clinical, pharmacokinetic, clinical and regulatory development) of biotechnological compounds and small molecules, leading to worldwide product registration (17+ years’ experience). Furthermore, she holds great experience in filing of INDs and BLAs/MAAs and in building and managing development teams ranging from several to 150+ people."